Home - Australian Pharmacist

Semaglutide for tobacco use disorder (nicotine dependence)

AP Staff - August 5, 2000

Clinical

References World Health Organisation. Tobacco Geneva, Switzerland: World Health Organisation. 2025. At: www.who.int/news-room/fact-sheets/detail/tobacco Addiction Expert Group. Overview of tobacco smoking and nicotine dependence. 2023....

Is the banana question distracting from real potassium risks?

AP Staff - October 9, 2000

Clinical

When patients ask if they need to give up bananas, pharmacists can redirect the conversation to the real drivers of hyperkalaemia risk.

Key changes coming for pharmacists in 2026

Chloe Hava - December 15, 2001

Wooden block calendar with January 01 on red surface, horizontal shot. Clean photo symbolizing New Year and celebration. Concept of new year celebration

Practice

New year, new policy and practice changes. Here’s what pharmacists will need to navigate from January. In 2026, pharmacists can expect some changes to education,...

Whitfield’s ointment

AP Staff - October 9, 2000

Clinical

Homei A, Worboys M. Fungal Disease in Britain and the United States 1850–2000: Mycoses and Modernity. Chapter 2: Athlete’s foot: a disease of...

Confidence, rebottled

Ruth Cooper - November 13, 2000

Industry

References Cancer Council Australia. Skin cancer incidence and mortality 2025. At: www.cancer.org.au/about-us/policy-and-advocacy/prevention/uv-radiation/related-resources/skin-cancer-incidence-and-mortality Cancer Council NSW. About skin cancer. 2024. At: www.cancercouncil.com.au/skin-cancer/about-skin-cancer/#common Serrels, Mark. We...

PSA standards for CPD for pharmacists now published

PSA staff - December 15, 2001

Practice

The Pharmaceutical Society of Australia (PSA) recently launched the PSA Standards for Continuing Professional Development (CPD) for Pharmacists, marking a new era for the...

1...314315316...318 Page 315 of 318

ACT³	No comparable criteria
NSW⁴	· pharmacist gives the person an opportunity to seek advice as to the use of the substance · quantity, or for a purpose must accord with the recognised therapeutic standard of what is appropriate in the circumstances
NT⁵	· pharmacist must not intentionally supply to a person in a manner reckless to their circumstance
QLD⁶	· pharmacist reasonably believes the patient has a therapeutic need
SA	No comparable criteria
TAS⁷	· pharmacist forms the opinion use in the treatment of the patient is justified on consideration of the condition, disease or symptoms of the person
VIC⁸	· for treatment of a patient under pharmacist’s care · pharmacist has taken all reasonable steps to ensure a therapeutic need exists
WA⁹	No comparable criteria

ACT³	No comparable criteria
NSW⁴	· pharmacist gives the person an opportunity to seek advice as to the use of the substance · quantity, or for a purpose must accord with the recognised therapeutic standard of what is appropriate in the circumstances
NT⁵	· pharmacist must not intentionally supply to a person in a manner reckless to their circumstance
QLD⁶	· pharmacist reasonably believes the patient has a therapeutic need
SA	No comparable criteria
TAS⁷	· pharmacist forms the opinion use in the treatment of the patient is justified on consideration of the condition, disease or symptoms of the person
VIC⁸	· for treatment of a patient under pharmacist’s care · pharmacist has taken all reasonable steps to ensure a therapeutic need exists
WA⁹	No comparable criteria

ACT³	No comparable criteria
NSW⁴	· pharmacist gives the person an opportunity to seek advice as to the use of the substance · quantity, or for a purpose must accord with the recognised therapeutic standard of what is appropriate in the circumstances
NT⁵	· pharmacist must not intentionally supply to a person in a manner reckless to their circumstance
QLD⁶	· pharmacist reasonably believes the patient has a therapeutic need
SA	No comparable criteria
TAS⁷	· pharmacist forms the opinion use in the treatment of the patient is justified on consideration of the condition, disease or symptoms of the person
VIC⁸	· for treatment of a patient under pharmacist’s care · pharmacist has taken all reasonable steps to ensure a therapeutic need exists
WA⁹	No comparable criteria

ACT³	No comparable criteria
NSW⁴	· pharmacist gives the person an opportunity to seek advice as to the use of the substance · quantity, or for a purpose must accord with the recognised therapeutic standard of what is appropriate in the circumstances
NT⁵	· pharmacist must not intentionally supply to a person in a manner reckless to their circumstance
QLD⁶	· pharmacist reasonably believes the patient has a therapeutic need
SA	No comparable criteria
TAS⁷	· pharmacist forms the opinion use in the treatment of the patient is justified on consideration of the condition, disease or symptoms of the person
VIC⁸	· for treatment of a patient under pharmacist’s care · pharmacist has taken all reasonable steps to ensure a therapeutic need exists
WA⁹	No comparable criteria

Is advance provision of S3s legal?

But don’t we need to assess a patient’s therapeutic need?

So when is advanced supply of S3 OK?

What other things do I need to consider?

So what about the Rikodeine?

Table 1 – Legal requirements for pharmacists when prescribing Schedule 3 medicines

References

What motivated you to seek election as the next PSA National President?

What do you hope to achieve as PSA President?

Why do you feel this is such a pivotal moment for PSA and the profession?

What are the major challenges pharmacists are facing right now?

How do you see the profession evolving in 5 years?

How have your background and previous experiences shaped your views of the profession?

Case scenario

Learning objectives

Introduction

Aetiology and pathophysiology

Clinical features

Diagnosis, differential diagnosis and prognosis

Management and treatment

Knowledge to practice

Conclusion

Case scenario continued

Key points

References

Our authors

Our reviewer

Conflict of interest declaration

Wrong-patient supply leads to hospital admission

Labelling and selection errors

A stronger incident-reporting culture

Building a career in incident management

ALERT 1: Potential risk of suicidal thoughts

What does the product warning say?

What products are affected by this alert?

What should pharmacists do?

ALERT 2: Tirzepatide (Mounjaro) and contraception

Is it just tirzepatide (Mounjaro)?

Is advance provision of S3s legal?

But don’t we need to assess a patient’s therapeutic need?

So when is advanced supply of S3 OK?

What other things do I need to consider?

So what about the Rikodeine?

Table 1 – Legal requirements for pharmacists when prescribing Schedule 3 medicines

References

What motivated you to seek election as the next PSA National President?

What do you hope to achieve as PSA President?

Why do you feel this is such a pivotal moment for PSA and the profession?

What are the major challenges pharmacists are facing right now?

How do you see the profession evolving in 5 years?

How have your background and previous experiences shaped your views of the profession?

Case scenario

Learning objectives

Introduction

Aetiology and pathophysiology

Clinical features

Diagnosis, differential diagnosis and prognosis

Management and treatment

Knowledge to practice

Conclusion

Case scenario continued

Key points

References

Our authors

Our reviewer

Conflict of interest declaration

Wrong-patient supply leads to hospital admission

Labelling and selection errors

A stronger incident-reporting culture

Building a career in incident management

ALERT 1: Potential risk of suicidal thoughts

What does the product warning say?

What products are affected by this alert?

What should pharmacists do?

ALERT 2: Tirzepatide (Mounjaro) and contraception

Is it just tirzepatide (Mounjaro)?

Is advance provision of S3s legal?

But don’t we need to assess a patient’s therapeutic need?

So when is advanced supply of S3 OK?

What other things do I need to consider?

**ALERT 2: Tirzepatide (Mounjaro) and contraception**

**ALERT 2: Tirzepatide (Mounjaro) and contraception**

**ALERT 2: Tirzepatide (Mounjaro) and contraception**